Moore Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Moore Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-100,000	Closed	-$8.29M	–	754
2025 Q2	$8.29M	Buy	+100,000	New	+$7.98M	0.1%	159
2025 Q1	–	Sell	-245,500	Closed	-$22.1M	–	636
2024 Q4	$22.1M	Buy	+245,500	New	+$23.8M	0.25%	103
2024 Q2	–	Sell	-115,000	Closed	-$10.9M	–	559
2024 Q1	$10.9M	Sell	115,000 -285,000	-71%	-$26.4M	0.17%	117
2023 Q4	$35.7M	Buy	400,000 +225,000	+129%	+$16.7M	0.62%	30
2023 Q3	$12.8M	Buy	+175,000	New	+$14M	0.24%	81

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Moore Capital Management's XBI Position: Q1 2026 in Review

Moore Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 225,000 shares — an estimated $27.4M sold.

Moore Capital Management first reported a position in XBI in Q4 2016 and held it in 15 quarters. The position peaked at $264M in Q4 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Moore Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
Moore Capital Management sold 225,000 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $27.4M.
Moore Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 15 quarters.
Moore Capital Management's State Street SPDR S&P Biotech ETF position peaked at $264M in Q4 2022.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.